LURASIDONE HYDROCHLORIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (2010)
Entry Type: Small molecule
Molecule Category: Salt
UNII: O0P4I5851I
Parent Compound: LURASIDONE

Structure
InChI Key NEKCRUIRPWNMLK-SCIYSFAVSA-N
Smile Cl.O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1
InChI
InChI=1S/C28H36N4O2S.ClH/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26;/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2;1H/t18-,19+,20-,21-,24+,25-;/m0./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C28H37ClN4O2S
Molecular Weight 529.15
AlogP 4.26
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 5.0
Polar Surface Area 56.75
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 35.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Dopamine D2 receptor antagonist DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Schizophrenia 4 D012559 ClinicalTrials
Bipolar Disorder 4 D001714 ClinicalTrials
Bipolar Disorder 4 D001714 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Psychiatric disorders
27.06
Nervous system disorders
19.1
General disorders and administration site conditions
12.47
Injury, poisoning and procedural complications
7.89
Gastrointestinal disorders
5.52
Investigations
4.6
Musculoskeletal and connective tissue disorders
3.8
Skin and subcutaneous tissue disorders
3.18
Cardiac disorders
2.42
Vascular disorders
2.35
Respiratory, thoracic and mediastinal disorders
2.23
Metabolism and nutrition disorders
2.08

Cross References

Resources Reference
ChEBI 70732
ChEMBL CHEMBL1615372
FDA SRS O0P4I5851I
PubChem 11237860
SureChEMBL SCHEMBL1534132
ZINC ZINC33974796
CONTENTS